714 related articles for article (PubMed ID: 3498962)
1. Barrett's oesophagus: a clinical study of 52 patients.
Cooper BT; Barbezat GO
Q J Med; 1987 Feb; 62(238):97-108. PubMed ID: 3498962
[TBL] [Abstract][Full Text] [Related]
2. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
[TBL] [Abstract][Full Text] [Related]
4. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?
Stoltey J; Reeba H; Ullah N; Sabhaie P; Gerson L
Aliment Pharmacol Ther; 2007 Jan; 25(1):83-91. PubMed ID: 17229223
[TBL] [Abstract][Full Text] [Related]
5. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study.
Zagari RM; Fuccio L; Wallander MA; Johansson S; Fiocca R; Casanova S; Farahmand BY; Winchester CC; Roda E; Bazzoli F
Gut; 2008 Oct; 57(10):1354-9. PubMed ID: 18424568
[TBL] [Abstract][Full Text] [Related]
6. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
7. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
8. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
9. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
10. [Complications of Barrett's esophagus: indications for esophageal resection with special reference to high-grade dysplasia].
Catrambone G; Leoncini G; Iurilli L; Queirolo A; Spinelli A; Taviani M; Mazzarino S
Minerva Chir; 1999 Oct; 54(10):657-67. PubMed ID: 10575887
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
13. [Quantification of gastro-esophageal reflux in Barrett's esophagus].
Ortiz Escandell A; Martínez de Haro LF; Parrilla Paricio P; Molina Martínez J; Aguayo Albasini JL; Martínez Gómez D
Rev Esp Enferm Dig; 1990 Mar; 77(3):171-5. PubMed ID: 2378753
[TBL] [Abstract][Full Text] [Related]
14. Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus.
Smythe A; Bird NC; Troy GP; Globe J; Johnson AG
Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1149-53. PubMed ID: 9471019
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.
Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
Gut; 2008 Aug; 57(8):1056-64. PubMed ID: 18403496
[TBL] [Abstract][Full Text] [Related]
16. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
Armstrong D
Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
[TBL] [Abstract][Full Text] [Related]
17. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
Ladanchuk TC; Johnston BT; Murray LJ; Anderson LA;
Scand J Gastroenterol; 2010 Dec; 45(12):1397-403. PubMed ID: 20626305
[TBL] [Abstract][Full Text] [Related]
18. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
20. Review article: Barrett's oesophagus and carcinoma in Japan.
Hongo M
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
